Journal of Diagnostics Concepts & Practice >

2020 , Vol. 19 >Issue 03: 248 - 257

DOI: https://doi.org/10.16150/j.1671-2870.2020.03.009

Original article

Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application

Expand
  • 1. Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2a. Department of Clinical Laboratory, 2b. Department of Pathology, Shanghai Children′s Hospital, Shanghai 200040, China

Received date: 2019-07-22

  Online published: 2020-06-25

Fold

Abstract

Objective: To identify the differentially expressed genes of phosphatidylinositide3-kinase(PI3K), nuclear factor kappa-B(NF-κB) and RAS/RAF signal pathways at mRNA and protein levels in pediatric Burkitt lymphoma（BL） for exploring the correlation of these genes with the development and progression of BL and determining the specific target genes for diagnosis and treatment monitoring. Methods: Tumor tissues from 18 cases of pediatric BL and tissues of normal lymphnodes of 20 pediatric cases were collected. The expression levels of mRNA of related target genes in the pathways were analyzed by real-time fluorescence quantitative reverse transcription polymerase chain reaction and the protein levels were determined by immunohistochemistry. Results: The expressions of MYC, TCF3, ID3, CCDN3, CDK6, CDK4, NRAS, RAF1 at mRNA and protein levels were up-expressed significantly in BL and some target genes and its protein of NF-κB pathway such as BCL2, CD44, C-FLIP, CCND2 and A20 were suppressed in BL when compared with normal tissues (P<0.05). Cases carrying c-MYC translocation and BCL2 expression (BCL2+) had higher serum LDH levels (P<0.05). Conclusions: Expressions of MYC, TCF3, CCND3, CDK6, NRAS and RAF1 genes are high,which might be used as molecular markers for the diagnosis and treatment monitoring of pediatric BL. c-MYC gene translocation accompanied with BCL2+ might be an important molecular indicator in BL, which is correlated with high serum LDH level, indicating advanced tumor staging, high tumor burden, and poor prognosis.

Key words： Pediatric Burkitt lymphoma; Clinical molecular target; Fluorescence quantitative reverse transcription polymerase chain reaction; Immunohistochemistry

Cite this article

MENG Leijun, ZHANG Jing, WANG Xueli, LI Zhi, ZHANG Hong, ZENG Naiyan . Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application[J]. Journal of Diagnostics Concepts & Practice, 2020 , 19(03) : 248 -257 . DOI: 10.16150/j.1671-2870.2020.03.009

References

[1] Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead[J]. J Clin Oncol, 2015, 33(27):2963-2974.
[2] Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma[J]. N Engl J Med, 2006, 354(23):2431-2442.
[3] Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling[J]. N Engl J Med, 2006, 354(23):2419-2430.
[4] Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma[J]. Lancet, 2012, 379(9822):1234-1244.
[5] Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomage-nesis[J]. Cancer Cell, 2012, 22(2):167-179.
[6] Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics[J]. Nature, 2012, 490(7418):116-120.
[7] Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis[J]. Cell Death Differ, 2012, 19(7):1220-1227.
[8] Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives[J]. Pediatr Hematol Oncol, 2013, 30(6):465-483.
[9] 张梦, 金玲, 杨菁, 等. 儿童伯基特淋巴瘤186例临床特征及疗效分析[J]. 中华儿科杂志, 2018, 56(8):605-610.
[10] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390.
[11] Pitkin L, Luangdilok S, Corbishley C, et al. Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival[J]. Br J Cancer, 2007, 97(5):670-677.
[12] Lee S, Day NS, Miles RR, et al. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report[J]. Br J Haematol, 2017, 177(4):601-611.
[13] Cai Q, Medeiros LJ, Xu X, et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management[J]. Oncotarget, 2015, 6(36):38591-38616.
[14] Greenough A, Dave SS. New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing[J]. Curr Opin Hematol, 2014, 21(4):326-332.
[15] Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma[J]. Nat Genet, 2012, 44(12):1321-1325.
[16] 魏洁, 范林妮, 李侠, 等. 中国人Burkitt淋巴瘤中ID3、TCF3及MYC基因突变分析[J]. 临床试验与病理学杂志, 2016, 32(12):1343-1347.
[17] Cornall RJ, Cyster JG, Hibbs ML, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection[J]. Immunity, 1998, 8(4):497-508.
[18] Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3):153-166.
[19] Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma[J]. Pathology. 2018 Jan; 50(1):74-87.
[20] Yoshida M, Ichikawa A, Miyoshi H, et al. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma[J]. Pathol Int, 2015, 65(9):486-489.
[21] Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by coopera-tion between myc and Bcl-2[J]. Nature, 1990, 348(6299):331-333.
[22] 杨文萍, 黄慧, 宫丽平, 等. 儿童散发性伯基特淋巴瘤的分子遗传学特征分析[J]. 中华病理学杂志, 2010, 39(12):819-824.
[23] Criscuolo M, Fianchi L, Dragonetti G, et al. Tumor lysis syndrome: review of pathogenesis, risk factors and mana-gement of a medical emergency[J]. Expert Rev Hematol, 2016, 9(2):197-208.
Options
Outlines

/

〈 〉